Physician profile
Andrew Stone
NPI 1538108857
$3,968.08
in general payments reported to CMS, 2019-2025
26 companies · $3,004 in 2025
The $3,004 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $964 · 2025: $3,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,868 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.09 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $743.43 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $674.52 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $458.09 | 2024-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $253.93 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.39 | 2024-2025 | Ofev, Jascayd |
| Genzyme Corporation | $216.19 | 2024-2025 | |
| Verona Pharma, INC. | $170.60 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $136.39 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $119.73 | 2025 | Zerbaxa |
| Philips North America LLC | $109.66 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $107.41 | 2024 | Yupelri |
| Baxter Healthcare | $106.21 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $96.38 | 2025 | Purified Cortrophin Gel |
| Inogen, INC. | $95.84 | 2025 | |
| Lundbeck LLC | $80.64 | 2024-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $78.95 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $74.80 | 2024-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $56.37 | 2025 | Opsumit, Uptravi |
| 3b Medical, INC. | $25.98 | 2025 | Luna |
| Resmed Corp | $24.06 | 2024 | |
| Axsome Therapeutics, INC. | $22.91 | 2025 | Sunosi |
| Insmed, INC. | $19.63 | 2025 | Arikayce |
| Alnylam Pharmaceuticals INC. | $18.77 | 2025 | Amvuttra |
| Paratek Pharmaceuticals, INC. | $18.49 | 2025 | Nuzyra |
| Pfizer INC. | $17.20 | 2024 | |
| Medicomp INC | $13.51 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.